Introduction
Candida vulvovaginitis is one of the most common infections encountered by obstetricians and gynaeDepartment ofObstetrics and Gynaecology, University of Goteborg, Gidteborg Bushell and coworkers7 evaluated intermittent, local, premenstrual prophylaxis with a 500 mg clotrimazole vaginal tablet given at monthly intervals against an identical placebo regimen. The difference in recurrence rates after 3 months between premenstrual prophylaxis with a 500 mg clotrimazole vaginal tablet (53%) and placebo (76%) was not significant.
However, Sobel and coworkers8 demonstrated a moderate protection from recurrence by prophylactic treatment with clotrimazole.
The incidence of acute vaginal candidiasis reaches a maximum shortly before the onset of menstruation which may partially be due to changes in the cellular immune response to Candida albicans occurring during the menstrual cycle.9 Vaginal yeast counts have been shown to be directly related to the development of symptoms and clinical signs of candidiasis.'0 Yeast counts are at a minimum directly after menstruation and acute vaginal candidiasis is less commonly encountered in the immediate postmenstrual period. Thus, it would be reasonable to assume that prophylaxis given postmenstrually would be potentially more effective as the number of candida organisms is then at a minimum.
The aim of the present study was to assess the efficacy of intermittent postmenstrual prophylaxis with a single 500 mg clotrimazole vaginal tablet in women with recurrent vaginal candidiasis.
Patients and methods
Sixty four otherwise healthy women (age 28-1 SD 7T2 years), with a history of at least four episodes of The women were treated with a single 500 mg clotrimazole vaginal tablet and re-examined after one week. Women who were symptom-free after treatment and who had a negative culture for C albicans were invited to participate in this double-blind trial. Intermittent prophylactic treatment with a 500 mg clotrimazole vaginal tablet or placebo was administered postmenstrually for 6 months. The active and placebo vaginal tablets were indistinguishable. The containers were prepacked and randomised so that neither the clinician, mycologist, nor the patient knew which treatment was being given. The women were clinically and mycologically assessed one week after menstruation for a period of 6 months during which they received either a single 500 mg clotrimazole vaginal tablet or placebo which was inserted by the examining gynaecologist ( fig 1) . After 6 months of intermittent treatment the women were observed for an additional period of 6 months during which clinical and mycological assessments were performed at 9 and 12 months respectively. Davidson and Mould5 evaluated the efficacy of prophylactic treatment using local application of 100 mg clotrimazole for 6 days at monthly intervals. This prophylactic treatment regimen kept symptoms below a critical level but did not affect the return of yeasts to the vagina. Sobel6 studied the prophylactic use of oral ketokonazole in patients suffering from recurrent vulvovaginal candidiasis. Intermittent prophylaxis with ketokonazole was only partially successful as 24% of the women developed symptoms of vulvovaginal candidiasis during treatment and 57% developed symptoms within an additional 3 months after the cessation of treatment. Bushell and coworkers7 evaluated intermittent, local, premenstrual prophylaxis with a 500 mg clotrimazole vaginal tablet given at monthly intervals against an identical placebo regimen. The difference in recurrence rates after 3 months between premenstrual prophylaxis with a 500 mg clotrimazole vaginal tablet (53%) and placebo (76%) was not significant. However, Sobel and coworkers8 demonstrated a moderate protection from recurrence by prophylactic treatment with clotrimazole.
In the present study postmenstrual prophylactic treatment with a single 500 mg clotrimazole vaginal tablet was evaluated against placebo in women with recurrent vulvovaginal candidiasis. The women included in this study had experienced an average of 6 episodes of acute vulvovaginal candidiasis during the last 12 months prior to inclusion in this study. The correct diagnosis of the recurrent nature of the patients vulvovaginal candidiasis was confirmed by the fact that 60% ofthe women who received placebo This study has demonstrated that prophylactic treatment with a single 500 mg clotrimazole vaginal tablet, applied postmenstrually, at monthly intervals prevented recurrence of symptoms. When prophylaxis was terminated after 6 months, symptoms invariably returned. Thus, a continuous prophylactic regimen given at monthly intervals as described here may well provide a simple, effective alternative 
